{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05550246",
            "orgStudyIdInfo": {
                "id": "2022P001544"
            },
            "organization": {
                "fullName": "Brigham and Women's Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy",
            "officialTitle": "Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy",
            "therapeuticArea": [
                "Other"
            ],
            "study": "identifying-sleep-apnea-patients-that-best-respond-to-atomoxetine-plus-oxybutynin-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-05-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-19",
            "studyFirstSubmitQcDate": "2022-09-19",
            "studyFirstPostDateStruct": {
                "date": "2022-09-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-16",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Scott Aaron Sands",
                "investigatorTitle": "Assistant Professor of Medicine",
                "investigatorAffiliation": "Brigham and Women's Hospital"
            },
            "leadSponsor": {
                "name": "Brigham and Women's Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Atomoxetine-plus-oxybutynin therapy (AtoOxy) has been shown to substantially reduce obstructive sleep apnea severity (OSA) in about half of patients. Here, the investigators will study which patients respond meaningfully to therapy using pathophysiological traits measured at baseline sleep studies.",
            "detailedDescription": "The primary goal of the current study is to test the central hypothesis that therapeutic efficacy of AtoOxy depends on underlying patient pathophysiology.\n\nAim 1 - Advanced analysis of clinical polysomnography will be used to estimate the OSA traits and classify patients as 'predicted responders' or 'predicted nonresponders'. Investigators will prospectively test whether AtoOxy efficacy is greater in predicted responders.\n\nAim 2 - Pooling preliminary and prospective data, investigators will test the hypotheses that the following pathophysiological traits are associated with, and therefore predict, greater efficacy: less-severe upper airway collapsibility (less improvement needed to re-establish airflow), lower loop gain (less severe ventilatory control instability), higher arousal threshold (greater scope for muscle activation without arousal), and greater upper airway muscle compensation (functional muscle reflex apparatus).\n\nAim 3 - Investigators will test the hypothesis that treatment efficacy will be greater in patients with tongue-related upper airway obstruction per previous drug-induced sleep endoscopy results (anterior-posterior collapse patterns)."
        },
        "conditionsModule": {
            "conditions": [
                "Obstructive Sleep Apnea"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "Participants and outcome assessors will be blinded to physiological predicted responder status"
                }
            },
            "enrollmentInfo": {
                "count": 22,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AtoOxy Predicted Responders",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.",
                    "interventionNames": [
                        "Drug: Atomoxetine",
                        "Drug: Oxybutynin"
                    ]
                },
                {
                    "label": "AtoOxy Predicted Nonresponders",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.",
                    "interventionNames": [
                        "Drug: Atomoxetine",
                        "Drug: Oxybutynin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Atomoxetine",
                    "description": "Treatment given for 3 nights",
                    "armGroupLabels": [
                        "AtoOxy Predicted Nonresponders",
                        "AtoOxy Predicted Responders"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Oxybutynin",
                    "description": "Treatment given for 3 nights",
                    "armGroupLabels": [
                        "AtoOxy Predicted Nonresponders",
                        "AtoOxy Predicted Responders"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Apnea-hypopnea index (AHI)",
                    "description": "Apneas and hypopneas per hour (3% desat and/or arousal), % change from baseline",
                    "timeFrame": "3 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Hypoxic Burden",
                    "description": "Desaturation area under curve \u00d7 event frequency",
                    "timeFrame": "3 days"
                },
                {
                    "measure": "Arousal Index",
                    "description": "Number of arousals per hour (\\>=3-sec), % change from baseline",
                    "timeFrame": "3 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Suspected or diagnosed OSA\n* Recent drug induced sleep endoscopy results available (performed as part of routine clinical care).\n\nExclusion Criteria:\n\n* Any uncontrolled medical condition\n* Current use of the medications under investigation\n* Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).\n* Current use of hypnotic medications (trazodone, eszopiclone, benzodiazepines).\n* Current use of SNRIs/SSRIs or anticholinergic medications.\n* Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.\n* Respiratory disorders other than sleep disordered breathing: chronic hypoventilation/hypoxemia (awake SaO2 \\< 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions.\n* Other sleep disorders: periodic limb movements, narcolepsy, or parasomnias.\n* Contraindications for atomoxetine and oxybutynin, including:\n\n  * hypersensitivity to atomoxetine or oxybutynin (angioedema or urticaria)\n  * pheochromocytoma\n  * use of monoamine oxidase inhibitors\n  * benign prostatic hypertrophy, urinary retention\n  * untreated narrow angle glaucoma\n  * bipolar disorder, mania, psychosis\n  * history of major depressive disorder (age\\<24).\n  * history of attempted suicide or suicidal ideation within one year prior to screening\n  * clinically significant constipation, gastric retention\n  * pre-existing seizure disorders\n  * clinically-significant kidney disorders (eGFR\\<60 ml/min/1.73m2)\n  * clinically-significant liver disorders\n  * clinically-significant cardiovascular conditions\n  * moderate-to-severe hypertension (SBP\\>180 mmHg or DBP\\>110 mmHg measured at baseline; average of evening and morning measures\\*)\n  * cardiomyopathy (LVEF\\<50%) or heart failure\n  * advanced atherosclerosis\n  * history of cerebrovascular events\n  * history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation\n  * other serious cardiac conditions that would raise the consequences of an increase in blood pressure or heart rate\n  * myasthenia gravis\n* Claustrophobia\n* Pregnancy or nursing\n\n  n.b. Development of new hypertension that is recognized on the final day of study medications during outcomes collection will not be used as stopping criteria for discontinuing outcomes collection.\n\nParticipants that are sexually active and able to become pregnant must agree to use birth control for the entire study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Scott A Sands, PhD",
                    "role": "CONTACT",
                    "phone": "617-278-0911",
                    "email": "sasands@bwh.harvard.edu"
                },
                {
                    "name": "Laura K Gell, PhD",
                    "role": "CONTACT",
                    "phone": "617-525-9086",
                    "email": "lgell@bwh.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Scott A Sands, PhD",
                    "affiliation": "Brigham and Women's Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Brigham and Women's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02141",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Scott A Sands, PhD",
                            "role": "CONTACT",
                            "phone": "857-928-0341",
                            "email": "sasands@bwh.harvard.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Data will be available to researchers who provide a methodologically sound proposal.\n\nAll IPD collected during the study will be available after deidentification.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "Immediately after publication. No end date.",
            "accessCriteria": "1-page proposals should be directed to Dr. Scott Sands (sasands@bwh.harvard.edu). To gain access, requestors will be asked to sign a data use agreement."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001049",
                    "term": "Apnea"
                },
                {
                    "id": "D000012891",
                    "term": "Sleep Apnea Syndromes"
                },
                {
                    "id": "D000020181",
                    "term": "Sleep Apnea, Obstructive"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012120",
                    "term": "Respiration Disorders"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000012818",
                    "term": "Signs and Symptoms, Respiratory"
                },
                {
                    "id": "D000020919",
                    "term": "Sleep Disorders, Intrinsic"
                },
                {
                    "id": "D000020920",
                    "term": "Dyssomnias"
                },
                {
                    "id": "D000012893",
                    "term": "Sleep Wake Disorders"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M22010",
                    "name": "Sleep Apnea, Obstructive",
                    "asFound": "Obstructive Sleep Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4361",
                    "name": "Apnea",
                    "asFound": "Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15694",
                    "name": "Sleep Apnea Syndromes",
                    "asFound": "Sleep Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M14957",
                    "name": "Respiration Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15623",
                    "name": "Signs and Symptoms, Respiratory",
                    "relevance": "LOW"
                },
                {
                    "id": "M22242",
                    "name": "Parasomnias",
                    "relevance": "LOW"
                },
                {
                    "id": "M22654",
                    "name": "Sleep Disorders, Intrinsic",
                    "relevance": "LOW"
                },
                {
                    "id": "M22655",
                    "name": "Dyssomnias",
                    "relevance": "LOW"
                },
                {
                    "id": "M15696",
                    "name": "Sleep Wake Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000005419",
                    "term": "Oxybutynin"
                },
                {
                    "id": "D000069445",
                    "term": "Atomoxetine Hydrochloride"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018759",
                    "term": "Adrenergic Uptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000010276",
                    "term": "Parasympatholytics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000018727",
                    "term": "Muscarinic Antagonists"
                },
                {
                    "id": "D000018680",
                    "term": "Cholinergic Antagonists"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000064804",
                    "term": "Urological Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M227675",
                    "name": "Oxybutynin",
                    "asFound": "Arm description",
                    "relevance": "HIGH"
                },
                {
                    "id": "M414",
                    "name": "Atomoxetine Hydrochloride",
                    "asFound": "Equipment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M13189",
                    "name": "Parasympatholytics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20801",
                    "name": "Muscarinic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20760",
                    "name": "Cholinergic Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Urol",
                    "name": "Urological Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}